IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)

P. Galle,R. S. Finn, S. Qin, M. Ikeda,M. Ducreux,T. -Y Kim, H. Y. Lim, M. Kudo,V Breder,P. Merle,A. Kaseb,D. Li,W. Verret, H. Shao, J. Liu, L. Li,A. X. Zhu, A. -L Cheng

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 263|浏览14

暂无评分

摘要

267Background: Atezo + bev has been approved globally for pts with unresectable HCC who have not received prior systemic therapy, based on results from IMbrave150 (NCT03434379). At a median of 8.6 ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要